Guest blog post by Dr Scott Webster, University of Kentucky, USA
Can Alzheimer’s disease memory problems be studied in a mouse model? A study published today in Alzheimer’s Research & Therapy attempts to answer this question by performing a comprehensive characterization of age-related behavioral changes in an important mouse model of Alzheimer’s disease.
A variety of behavioral tasks that measure motor performance, anxiety-like behavior, and cognitive ability were determined through the lifespan of the mice, ranging from young (7 month old), middle age (11 and 15 months old), and old (24 months old) mice. There were no impairments in motor function or anxiety-like behavior in the mice at any age tested. However, the mice developed Alzheimer-like memory problems as …
This week is the Alzheimer’s Society’s Dementia Awareness Week and Alzheimer’s Research & Therapy is talking about the impact of genetic variants on Alzheimer’s disease (AD).
AD is the most common form of dementia in older people and is characterized by behavioral disorders and a progressive decline in memory function. Genetic studies have provided the best evidence for cause and effect relationships in AD, and recent years have seen tremendous progress in genetics technology to allow for full individualized genomic screening across populations and within individuals.
Examples of the advances include identification of mutations in APP, PSEN1 and PSEN2 genes, which provided a link to the characteristic amyloid plaques seen in AD brains and supported the amyloid cascade hypothesis. Also, …
We are delighted to welcome Dr Philip Scheltens to his new position as one of the Editors-in-Chief of Alzheimer’s Research & Therapy, joining Dr Douglas Galasko (University of California, San Diego, USA) and Dr Todd Golde (University of Florida, USA). Dr Scheltens is replacing Dr Gordon Wilcock (University of Oxford, UK), who is stepping down from this role after many valuable years of guidance as Editor-in-Chief.
Dr Scheltens is Professor of Cognitive Neurology and Director of the Alzheimer Centre at the VU University Medical Centre in Amsterdam, which he founded in 2000. Dr Scheltens is active in the field of biomarkers and clinical trials, with his main clinical and research interests including Alzheimer’s disease, vascular dementia, frontotemporal dementia, …
Cognitive aging in the brain affects all of us, and is the focus of a new thematic series launched in Alzheimer’s Research & Therapy.
Aging can be associated with relatively little cognitive decline. But for some, it can lead to mild cognitive impairment (MCI), or cause a severe loss in cognitive function and result in dementia. Alzheimer’s disease (AD) is the most common form of dementia in older people and is characterized by behavioural disorders and a progressive decline in memory function.
In recent decades, there have been significant advances in our understanding of cognitive aging, but little advance in translating this knowledge into therapeutics. The AD epidemic is a looming crisis and there is an urgent need for …
Alzheimer’s Research & Therapy is now accepting research submissions for consideration in a special series on abeta catabolism, planned for publication in late 2013.
The publication of these articles will be co-ordinated with a series of commissioned reviews and opinions, guest edited by Dr Elizabeth Eckman (Atlantic Health) and written by leaders in the field including Gary Landreth (Case Western Reserve), Kristin Wildsmith (Genentech), Malcolm Leissring (Mayo clinic), Anthony Turner (Leeds) and Salvatore Oddo (UT Health Science Centre).
Submit your paper to this series and receive a 50% article processing charge discount – simply quote ‘AlzRTabeta’ at submission.
We welcome research manuscripts to accompany a series of articles reviewing the evidence for decreased Abeta clearance …
The second most common form of dementia in younger people is the focus of a thematic series from Alzheimer’s Research & Therapy.
Frontotemporal dementia (FTD) is a rare form of dementia that affects certain areas of the brain. The pathogenic genetic mutation responsible was only identified in 2011 and led to an avalanche of research in this area. Series Editor, Professor Bruce Miller, explains: “the C9ORF72 mutation is the most common mutation associated with both FTD and amyotrophic lateral sclerosis (ALS) in the Western hemisphere and Europe (less is known about C9ORF72 in Asia and Africa). It is a gene with strong penetrance, and the vast majority of subjects with C9ORF72 die from a neurodegenerative condition.”
In a …
Alzheimer’s Research & Therapy is newly affiliated to Alzheimer’s Disease International (ADI), the international federation of national Alzheimer organisations.
ADI provides a global voice for dementia, empowering national Alzheimer associations to promote and offer services and support for people with dementia and their carers. ADI works globally to focus attention on the Alzheimer’s epidemic, by hosting an annual conference and campaigning for policy change from governments and the World Health Organisation (WHO). For example, ADI commission a number of World Alzheimer Reports and were involved in the recently launched report Dementia: A Public Health Priority by the WHO. Read the highlights of the report in Alzheimer’s Research & Therapy.
Alzheimer’s Research & Therapy shares …
Alzheimer’s Research & Therapy is now accepting research submissions for consideration in a special series on peripheral biomarkers, planned for publication in summer 2013.
The publication of these articles will be co-ordinated with a series of commissioned reviews and opinions, edited by Douglas Galasko (UCSD) and written by leaders in the field including Thomas Kodadek (The Scripps Research Institute), Ralph Martins (Edith Cowans University), Sudha Seshadri (Boston) and John Trojanowski (Pennsylvania).
Submit your paper to this series and receive a 50% article processing charge discount – simply quote ‘alzrtPB’ at submission.
A huge research effort has been expended on identifying peripheral biomarkers in plasma, serum or blood cells, in …
‘Alcohol-related cognitive impairment’ is expected to become more common in the future as levels of alcohol consumption increase worldwide. As symptoms can be very similar to Alzheimer’s disease, there is increasing clinical demand to distinguish this as a separate disorder.
Alcohol-related cognitive disorders are currently split into two categories: alcohol related dementia (ARD) and alcohol-induced persisting amnestic syndrome (Wernicke-Korsakoff syndrome, or WKS). ‘Alcohol-related brain damage’ is increasingly used as an umbrella term to cover the heterogeneity of the disorders.
According to current DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th edition) criteria, ARD is caused by the direct and indirect effects of alcohol on the brain, which occur after several years of alcohol abuse. Symptoms of ARD are similar to …
Millions of people around the world suffer from neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis and Huntington’s disease. Neurodegenerative diseases primarily affect an older population, and as we continue to live longer, incidences of these are expected to soar. Finding treatments and cures for neurodegenerative diseases is therefore a goal of increasing urgency.
Advancing the development of new drugs for neurodegenerative diseases is the target for scientists brought together at the 7th Annual Drug Discovery for Neurodegeneration Conference, hosted by the Alzheimer’s Drug Discovery Foundation (ADDF).
ADDF is a public charity supporting the advancement of drugs to prevent, treat, and cure Alzheimer’s disease, related dementias, and cognitive aging.
On 10-12 February 2013, academic …